Galectin readies subscription rights offering

|About: Galectin Therapeutics,... (GALT)|By:, SA News Editor

Galectin Therapeutics (NASDAQ:GALT) has filed a prospectus for a subscription rights offering to shareholders to purchase one unit for each share owned.

Each unit will consist of 0.3 of a common share and one seven-year warrant to purchase 0.075 of a common share.

In a best-case scenario, the offering will raise ~$70M.

Shares are up 1% after hours.

Subscribe for full text news in your inbox